Literature DB >> 32477015

The association between RDW and survival of patients with squamous cell carcinoma of the tongue. Simple, cheap and convenient?

Marcin Miszczyk1, Iwona Jabłońska1, Łukasz Magrowski1, Oliwia Masri1, Paweł Rajwa2.   

Abstract

AIM: The purpose of this study was to evaluate the prognostic impact of red-cell distribution width (RDW) on the overall survival (OS) of patients with squamous cell carcinoma (SCC) of the tongue.
BACKGROUND: Development of cancer is connected with an ongoing inflammatory process which is reflected by laboratory indices, such as RDW that can be used as prognostic tools.
MATERIAL AND METHODS: The study group consists of 74 consecutive patients treated with radical radiotherapy or chemo-radiotherapy for SSC of the tongue at one institution between 2005-2014. RDW was assessed based on routine blood tests done before the start of the treatment. ROC curve was applied to assess value of RDW in prediction of OS, and a cut-off value for further tests was obtained using the Younden index. The survival analysis was performed using the Kaplan-Meier method, log-rank testing and Cox regression model.
RESULTS: The AUC for RDW in ROC analysis was 0.703, and the optimal cut-off value was 13.5%. 5-year OS was significantly lower in patients with RDW ≥ 13.5% compared with patients with RDW < 13.5% (67% vs. 26%, p-value = 0.0005). Additionally, high RDW was associated with a greater odds ratio for 5-year OS in a multivariate Cox proportional hazards regression analysis (3.43, 1.62-7.25; p = 0.001).
CONCLUSION: Our study demonstrated that pre-treatment RDW ≥ 13,5% is an indicator of poor overall survival in patients with SCC of the tongue. Since RDW is a cheap and convenient marker, usually routinely assessed during complete blood count tests, it could be further used as an additional prognostic tool in patients with tongue cancers.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  RDW; Radiotherapy; Red cell distribution width; Tongue cancer

Year:  2020        PMID: 32477015      PMCID: PMC7251531          DOI: 10.1016/j.rpor.2020.03.026

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  28 in total

1.  Split-course accelerated hyperfractionated irradiation (CHA-CHA) as a sole treatment for advanced head and neck cancer patients-final results of a randomized clinical trial.

Authors:  L Miszczyk; B Maciejewski; A Tukiendorf; G Woźniak; B Jochymek; A Gawryszuk; M Szweda
Journal:  Br J Radiol       Date:  2014-07-16       Impact factor: 3.039

2.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.

Authors:  Krzysztof Skladowski; Boguslaw Maciejewski; Maria Golen; Rafal Tarnawski; Krzysztof Slosarek; Rafal Suwinski; Mariusz Sygula; Andrzej Wygoda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

3.  Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody.

Authors:  Tatsunori Kiriu; Masatsugu Yamamoto; Tatsuya Nagano; Kiyoko Koyama; Masahiro Katsurada; Daisuke Tamura; Kyosuke Nakata; Motoko Tachihara; Kazuyuki Kobayashi; Yoshihiro Nishimura
Journal:  In Vivo       Date:  2019 Jan-Feb       Impact factor: 2.155

Review 4.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Authors:  Maura L Gillison; Anil K Chaturvedi; William F Anderson; Carole Fakhry
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.

Authors:  Brady E Beltran; Sally Paredes; Denisse Castro; Esther Cotrina; Eduardo M Sotomayor; Jorge J Castillo
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-15

6.  The growing burden of cancer in India: epidemiology and social context.

Authors:  Mohandas K Mallath; David G Taylor; Rajendra A Badwe; Goura K Rath; V Shanta; C S Pramesh; Raghunadharao Digumarti; Paul Sebastian; Bibhuti B Borthakur; Ashok Kalwar; Sanjay Kapoor; Shaleen Kumar; Jennifer L Gill; Moni A Kuriakose; Hemant Malhotra; Suresh C Sharma; Shilin Shukla; Lokesh Viswanath; Raju T Chacko; Jeremy L Pautu; Kenipakapatnam S Reddy; Kailash S Sharma; Arnie D Purushotham; Richard Sullivan
Journal:  Lancet Oncol       Date:  2014-04-11       Impact factor: 41.316

7.  The Relationship Between Red Cell Distribution Width and Cancer-Specific Survival in Patients With Renal Cell Carcinoma Treated With Partial and Radical Nephrectomy.

Authors:  Marcin Życzkowski; Paweł Rajwa; Ewa Gabrys; Karolina Jakubowska; Ewelina Jantos; Andrzej Paradysz
Journal:  Clin Genitourin Cancer       Date:  2017-12-27       Impact factor: 2.872

Review 8.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

Authors:  Francesco Colotta; Paola Allavena; Antonio Sica; Cecilia Garlanda; Alberto Mantovani
Journal:  Carcinogenesis       Date:  2009-05-25       Impact factor: 4.944

Review 9.  Prognostic value of RDW in cancers: a systematic review and meta-analysis.

Authors:  Linhui Hu; Manman Li; Yangyang Ding; Lianfang Pu; Jun Liu; Jingxin Xie; Michael Cabanero; Jingrong Li; Ru Xiang; Shudao Xiong
Journal:  Oncotarget       Date:  2017-02-28

10.  Pretreatment Level of Red Cell Distribution Width as a Prognostic Indicator for Survival in a Large Cohort Study of Male Laryngeal Squamous Carcinoma.

Authors:  Chi-Yao Hsueh; Hui-Ching Lau; Shengjie Li; Lei Tao; Ming Zhang; Hongli Gong; Liang Zhou
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

View more
  1 in total

1.  The prognostic value of red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in radiotherapy for oropharyngeal cancer.

Authors:  Emilia Staniewska; Bartłomiej Tomasik; Rafał Tarnawski; Mateusz Łaszczych; Marcin Miszczyk
Journal:  Rep Pract Oncol Radiother       Date:  2021-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.